ideasIdea
Cap public prices for new cancer drugs to tiers of the ESMO and ASCO value scales
Oncology societies already grade how much benefit each new drug gives. Payers should tie the maximum price they pay to that grade.
The ESMO Magnitude of Clinical Benefit Scale and ASCO Value Framework grade drugs by survival gain, quality of life and toxicity, but prices bear little relation to the grades; several analyses find no correlation between price and benefit. The proposal is for a coalition of public payers to publish a price corridor per benefit tier (for example a multiple of GDP per capita per life-year gained for grade 4-5 versus a much lower ceiling for grade 1-2) and to make the tier a binding input to negotiation, with prices revisited when confirmatory data change the grade.
Hypothesis
Payers adopting tiered ceilings pay prices correlated with benefit (Spearman rho above 0.5, from near zero today) and see lower growth in oncology drug spend without reducing the number of high-benefit drugs reimbursed.
Rationale
Transparent, benefit-linked ceilings give manufacturers a predictable target and reward developing drugs with large effects; the absence of any benefit-price relationship is the clearest symptom of a broken market.
What would test it
Retrospectively apply tiered ceilings to the last decade of oncology approvals in one country to model spend and access; then adopt prospectively in a coalition of two or three payers and measure correlation and spend after three years.
Maturity
speculative
Who has to act
payer
Cost to try
Small (under $1M)
Years to first evidence
3
Bottlenecks it attacks
- Prices and value · New cancer drugs routinely cost over $150,000 a year, often for months of benefit. Systems cannot afford them and patients go bankrupt.
- Incentives reward me-too drugs and marginal gains · The system pays the same for a drug that adds two months as for a cure, so companies race to copy rather than to cure.